Business Wire

IRVINE, Calif.--(BUSINESS WIRE)-- The second day of the 11th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF) on the UC Irvine campus, underscored the theme of collaboration as essential in creating a future in which no patients are harmed by preventable medical errors and technologies continue to evolve at an accelerated pace to advance patient care.

This press release features multimedia. View the... (continue reading...)

The firms emphasized that the removal of blanket exclusions would catalyze Ukraine’s growth and future reconstruction

MONTE CARLO, Monaco--(BUSINESS WIRE)-- Aon and Marsh McLennan today called on the (re)insurance industry to build upon the capital, expertise and historical role of the (re)insurance industry to help Ukraine’s resilience by catalyzing economic growth and strengthening the country’s foundations for a post-conflict economy. The firms emphasized that... (continue reading...)

Board Received Proposal from MNC on Friday Evening that Expires on Monday

ANOKA, Minn.--(BUSINESS WIRE)-- Vista Outdoor Inc.’s (“Vista Outdoor”, the “Company”) (NYSE: VSTO) Board of Directors today commented on MNC Capital’s (“MNC”) most recent communication:

The Vista Outdoor Board of Directors has been negotiating extensively with MNC. Notwithstanding our good faith efforts, MNC sent the Board a revised proposal last evening after 10:00 PM ET that expires on... (continue reading...)

The fashion designer selected the beloved bedding brand’s rarest fabrication for his Spring 2025 ready-to-wear collection at New York Fashion Week.

NEW YORK--(BUSINESS WIRE)-- Beloved luxury bedding brand Boll & Branch makes its runway debut in a first-of-its-kind collaboration at New York Fashion Week, with esteemed fashion designer Prabal Gurung crafting ready-to-wear out of the brand’s sheeting fabric. All 100% organic cotton featured in the show is the brand’s... (continue reading...)

• Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
• 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan... (continue reading...)